Anaptysbio (ANAB) Other Non-Current Liabilities (2016 - 2026)

Anaptysbio (ANAB) has 10 years of Other Non-Current Liabilities data on file, last reported at $263.7 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 20.17% year-over-year to $263.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263.7 million (down 20.17% YoY) and the FY2025 annual result came in at $276.5 million, down 21.76% from the prior year.
• Other Non-Current Liabilities fell to $263.7 million in Q1 2026, from $276.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $362.0 million in Q2 2024 to a low of $35.0 million in Q3 2022.
• A 5-year average of $294.5 million and a median of $310.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities soared 789.35% — and 2025, when it decreased 21.76%.
• Tracing ANAB's Other Non-Current Liabilities over 5 years: stood at $304.4 million in 2022, then climbed by 2.1% to $310.8 million in 2023, then grew by 13.71% to $353.4 million in 2024, then dropped by 21.76% to $276.5 million in 2025, then slipped by 4.62% to $263.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $263.7 million (Q1 2026), $276.5 million (Q4 2025), and $331.8 million (Q3 2025), per Business Quant data.